# Muscular Atrophy, Spinal FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/muscular-atrophy-spinal

> 4 upcoming FDA catalysts in muscular Atrophy, Spinal: salanersen (BIIB) on Nov 2028 to Feb 2029 (topline data readout); salanersen (BIIB) on November 2028 (primary completion); salanersen (BIIB) on Jul to Oct 2029 (topline data readout); salanersen (BIIB) on July 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 30, 2026 | [SPINRAZA (nusinersen) primary completion](https://sec-api.dev/pdufa/nusinersen) | BIIB | Muscular Atrophy, Spinal | completed | "NCT04729907 (A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-30 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04729907)) |
| Nov 2028 to Feb 2029 | [Salanersen topline data readout](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07221669 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221669)) |
| November 2028 | [Salanersen primary completion](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07221669 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221669)) |
| Jul to Oct 2029 | [Salanersen topline data readout](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07444450 (A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444450)) |
| July 2029 | [Salanersen primary completion](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07444450 (A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444450)) |

## Drugs

- [SPINRAZA (nusinersen)](https://sec-api.dev/pdufa/nusinersen) (BIIB)
- [Salanersen](https://sec-api.dev/pdufa/salanersen) (BIIB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/muscular-atrophy-spinal.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Muscular Atrophy, Spinal FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/muscular-atrophy-spinal

```bibtex
@misc{secapidev_indications_muscular_atrophy_spinal_20261116,
  title        = {Muscular Atrophy, Spinal FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/muscular-atrophy-spinal}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_muscular_atrophy_spinal_20261116","title":"Muscular Atrophy, Spinal FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/muscular-atrophy-spinal","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
